Ken Griffin Celldex Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 83,900 shares of CLDX stock, worth $2.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

83,900

Previous 12,200 587.7%

Holding current value

$2.3 Million

Previous $451,000 531.93%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$32.06 - $44.56 $16.9 Million - $23.4 Million	526,069 Added 163.78%	847,281 $28.8 Million
Q2 2024 Aug 14, 2024	BUY	$32.76 - $42.56 $7.72 Million - $10 Million	235,766 Added 275.92%	321,212 $11.9 Million
Q1 2024 May 15, 2024	SELL	$35.22 - $51.88 $1.44 Million - $2.12 Million	-40,882 Reduced 32.36%	85,446 $3.59 Million
Q4 2023 Feb 14, 2024	BUY	$22.61 - $40.65 $2.72 Million - $4.89 Million	120,403 Added 2032.12%	126,328 $5.01 Million
Q3 2023 Nov 14, 2023	SELL	$25.45 - $37.46 $2.16 Million - $3.18 Million	-84,825 Reduced 93.47%	5,925 $163,000
Q2 2023 Aug 14, 2023	SELL	$30.29 - $38.28 $37.7 Million - $47.7 Million	-1,244,796 Reduced 93.21%	90,750 $3.08 Million
Q1 2023 May 15, 2023	BUY	$34.78 - $47.43 $20 Million - $27.3 Million	575,292 Added 75.67%	1,335,546 $48.1 Million
Q4 2022 Feb 14, 2023	SELL	$27.78 - $45.38 $20.6 Million - $33.6 Million	-740,840 Reduced 49.35%	760,254 $33.9 Million
Q3 2022 Nov 14, 2022	BUY	$22.7 - $37.57 $10.4 Million - $17.2 Million	457,067 Added 43.78%	1,501,094 $42.2 Million
Q2 2022 Aug 15, 2022	SELL	$20.5 - $37.33 $1.87 Million - $3.4 Million	-91,086 Reduced 8.02%	1,044,027 $28.1 Million
Q1 2022 May 16, 2022	BUY	$27.64 - $39.32 $1.82 Million - $2.59 Million	65,757 Added 6.15%	1,135,113 $38.7 Million
Q4 2021 Feb 14, 2022	BUY	$35.68 - $56.27 $10.2 Million - $16.1 Million	286,295 Added 36.56%	1,069,356 $41.3 Million
Q3 2021 Nov 15, 2021	BUY	$28.95 - $55.99 $11.9 Million - $23.1 Million	411,890 Added 110.97%	783,061 $42.3 Million
Q2 2021 Aug 16, 2021	SELL	$20.71 - $35.37 $12.5 Million - $21.4 Million	-604,845 Reduced 61.97%	371,171 $12.4 Million
Q1 2021 May 17, 2021	SELL	$16.19 - $29.91 $6.81 Million - $12.6 Million	-420,500 Reduced 30.11%	976,016 $20.1 Million
Q4 2020 Feb 16, 2021	BUY	$14.99 - $22.75 $20.6 Million - $31.2 Million	1,371,367 Added 5452.97%	1,396,516 $24.5 Million
Q3 2020 Nov 16, 2020	SELL	$9.65 - $15.19 $331,564 - $521,913	-34,359 Reduced 57.74%	25,149 $373,000
Q2 2020 Aug 14, 2020	BUY	$1.61 - $13.41 $56,345 - $469,309	34,997 Added 142.78%	59,508 $774,000
Q1 2020 May 15, 2020	BUY	$1.55 - $3.07 $13,596 - $26,930	8,772 Added 55.73%	24,511 $41,000
Q4 2019 Feb 14, 2020	BUY	$2.11 - $2.8 $33,209 - $44,069	15,739 New	15,739 $35,000

Others Institutions Holding CLDX

# of Institutions

207

Shares Held

67.3M

Call Options Held

1.69M

Put Options Held

980K

View Full List

About Celldex Therapeutics, Inc.

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.28B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

More about CLDX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account